Ceva reported Q2 2026 revenue of $29.0 million, up 13% YoY, with licensing and related revenue rising 21% to $18.2 million, a three-year high. The quarter featured ten IP licensing deals, including a NeuPro-M NPU license with a leading global AI platform, and continued connectivity royalty growth. Non-GAAP margins improved to 11% on disciplined cost management, supporting a healthier cash-flow trajectory.
Italy's tax police have seized €27.4 million from CEVA Logistics due to ongoing investigations into tax fraud and illegal labor practices. This development could signal significant legal and operational challenges for CEVA in the region, potentially impacting future cash flows and financial health.
CEVA is nearing completion of its Adhishthana cycle, now in Phase 18, which indicates a subdued outlook. This suggests potential weakness in CEVA's stock performance and may lead to caution among investors.
Ceva Animal Health raised €5.5 billion, increasing valuation to €9.2 billion. Bettencourt-Meyers family boosted their stake in Ceva, indicating strong investor confidence.